團隊
全福之研發營運團隊以台灣為基地,結合具經驗豐富的研發與營運管理⼈才組成,熟悉國內⽣技社群、研發態勢、及法規環境。全福同仁與海外資深專家共同組成⾼度整合之團隊,以最專業的經驗提⾼新藥開發之效率及成功率,並創造具體之產業貢獻。海外資深技術團隊及台灣研發營運⼯作團隊均擁有豐沛的國際⼈脈與研發網絡,有助於創新藥物案源之取得,及未來授權出場之商機會。
全福的資深專家技術團隊皆具國外⼤藥廠新藥開發實績,其專長包括新藥開發價值鏈各主要環節,包括前臨床及毒理、技術與藥物開發、臨床藥理與管理、臨床及法規策略、專利與臨床醫師建議等,使本公司以國際化研發規格開發新藥。
轉譯科學
專案管理
BRIM R&D
Operational Team
BRIM R&D
Operational Team
臨床前 & 毒理
Dr. Frank Lee
Chief Strategy Officer & Chief Scientific Officer
Dr. Frank Lee
Chief Strategy Officer
Dr. Carl Alden
Senior Fellow
Dr. Carl Alden
Senior Fellow
Previously Vice President at Millennium
Held various roles at Searle, Monsanto, Pharmacia & P&G
Served as Editor of Veterinary Pathology and Toxicology Pathology and President at Society of Toxicology Pathologist
臨床藥理學 & 臨床管理
Dr. Haishan Jang
Chairwoman & Chief Executive Officer
Dr. Haishan Jang
Chairwoman & Chief Executive Officer
Dr. Conrad Tou
Senior Fellow
Dr. Conrad Tou
Senior Fellow
30+ years of experience in biotech and large pharmaormer director at Hollis-Eden pharma
Held several positions at Sanofi-Winthrop and AstraZeneca, with expertise in statistics and data management
技術 &
藥品開發
Dr. Wayne Liaw
Senior Fellow
Dr. Wayne Liaw
Senior Fellow
Previously held Senior Director positions at Otonomy and Optimer
Former director at Hollis-Eden pharma
法規
Su Lin
VP of Operation
Su Lin
VP of Operation
市場行銷& IP
Dr. Chyau Liang
Senior Fellow
Dr. Chyau Liang
Senior Fellow
Previously Partner at Osha Liang LLP
Former Professor at the University of Texas-Houston School of Medicine
臨床專家 & KOLs(Ad hoc)
Dr. Pan-Chyr Yang
Scientific Board Member
Dr. Pan-Chyr Yang
Scientific Board Member
Academician at Academia Sinica and Professor at National Taiwan University
Previously President of National Taiwan University
Editor-in-Chief of MicroRNA and Lung Cancer: Targets and Therapy
Dr. Robert Ruffolo
Scientific Board Member
Dr. Robert Ruffolo
Scientific Board Member
Previously President of R&D and Corporate Senior Vice President of Wyeth Pharmaceuticals
Senior Vice President and Director of Research at SmithKline Beecham Pharmaceuticals
Chairman of the Cardiovascular Research Committee at Eli Lilly & Company
Dr. Wen Chyi Shyu
Scientific Board Member
Dr. Wen Chyi Shyu
Scientific Board Member
Vice President of Global Drug Metabolism and Pharmacokinetics at Takeda
30+ years of experience in drug metabolism and pharmacokinetics
Dr. Eliot Lazar
Scientific Board Member
Dr. Eliot Lazar
Scientific Board Member
CEO at elCON Medical Consulting
Previously held Assistant Professor positions at the State University of NY and the University of Rochester
核心經營團隊
簡博⼠在國際藥業已有超過30年的經驗,曾任職於Sterling Winthrop(Kodak)、Sanofi、DuPont、Centocor(J&J)等國際知名⼤藥廠擔任資深⾼階主管,並參與Uroxatral®, Tirazon®, Remicade®, Simponi®, and Stelara®等多種國際新藥研發工作,也曾於亞洲區負責Centocor(J&J)亞洲CRO/CMO評估及策略合作⼯作。返台後先後擔任生物技術開發中心資深顧問、工研院生醫所技術長、台灣生技整合育成中心(SI2C)營運長、安成生技總經理等。
李博士為UC San Francisco 藥物化學博士,在國際藥業已有超過40年的研發經驗,曾任職於美國Millennium Pharmaceuticals、DuPont Pharmaceuticals 、Glaxo, GlaxoWellcome 和 Syntex Research Institute 等國際大藥廠。在Millennium Pharmaceuticals(Takeda)服務期間擔任非臨床部DMPK 副總並參與公司各研發相關委員會,為公司研發案審核及決策成員。曾參與15 個FDA 批准上市新藥研發工作。
張副總畢業於台灣大學醫學院毒理研究所,
林副總畢業於美國天普大學藥劑學院藥物醫院管理碩士,具豐富之產業經驗,曾於美國任職Intercept Pharmaceuticals, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Wyeth Collegeville等跨國大藥廠,在 Regulatory Affairs 及 Labeling 領域更有近20年的實戰經驗。
陳博士原為細胞免疫學家,專長於T細胞和B細胞活性調控的研究,
吳副總畢業於成功大學會計系,並從美國舊金山金門大學取得會計碩士學位。曾經歷新創公司及上市櫃公司財會各領域職務達20幾年,學經歷豐富並擁有相當的實戰經驗。
研究發展團隊
Alden |特聘毒理專家
Dr. Alden, DVM/DACVP 具有超過41年製藥產業之經驗,具備獸醫師資格,專長於毒理學、病理學,先後任職Millennium、Searle、Monsanto、Pharmacia、P & G等國際大藥廠,並曾擔任Millennium Pharmaceuticals(Takeda)副總裁主管藥物安全。
Tou |特聘統計學專家
Dr. Tou有超過33年的製藥產業經驗,專長於統計及數據資料管理,先後服務於Sanofi-Synthelabo、Sterling-Winthrop、P & G 及Astra Zeneca等藥廠,在AstraZeneca服務時擔任統計長兼副主任。
Liang |特聘專利律師
Dr. Liang 擔任本公司專利顧問,現為美國歐夏梁高級合夥人、美國律師、專利代理人、台灣專利師,專精於美國、台灣等國際專利策略分析,有超過32年的經驗,熟悉專利申請與訴訟,及智慧財產管理和諮詢。
Liaw |特聘製劑學專家
Dr. Liaw 擔任本公司化學生產與控制顧問,專精於藥物劑型配方與生產製造開發,有超過30年以上經驗,對大分子、小分子或是胜肽配方開發、藥物傳輸開發、給藥途徑設計皆十分熟悉,曾於多家美國公司如Syntex、 Optimer Biotech等擔任資深主管工作。